Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)

Wuhan Hvsen Biotechnology Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	1,606	1,139	966.95	934.11	964.74	739.79
Other Revenue	61.09	61.09	52.81	88.79	31.48	37.67
Revenue	1,667	1,200	1,020	1,023	996.22	777.46
Revenue Growth (YoY)	48.74%	17.71%	-0.31%	2.68%	28.14%	81.98%
Cost of Revenue	1,233	1,006	809.11	800.16	727.71	491.59
Gross Profit	434.22	194.72	210.65	222.75	268.51	285.87
Selling, General & Admin	126.22	118.74	131.31	101.98	88.49	85.88
Research & Development	70.87	55.8	44.6	40.14	46.89	28.38
Other Operating Expenses	-2.01	3.52	3.23	8.84	4.92	4.41
Operating Expenses	201.57	176.37	204.08	161.73	133.23	123.43
Operating Income	232.65	18.35	6.57	61.01	135.28	162.43
Interest Expense	-20.6	-42.66	-28.22	-18.38	-2.87	-2.3
Interest & Investment Income	7.75	10.03	17.47	10.31	10.54	6.75
Currency Exchange Gain (Loss)	0.69	0.69	-0.16	-0.03	-0.03	-0.04
Other Non Operating Income (Expenses)	-3.14	-1.35	-0.62	-0.67	-0.47	-0.38
EBT Excluding Unusual Items	217.35	-14.96	-4.95	52.24	142.45	166.47
Gain (Loss) on Sale of Investments	20.19	-23.64	12.25	1.46	1.55	0.63
Gain (Loss) on Sale of Assets	-	-	-	0.01	-0.06	-
Asset Writedown	-0.34	-	-	-	-	-0.41
Other Unusual Items	9.62	9.62	5.14	3	6.89	9.34
Pretax Income	246.82	-28.97	12.44	56.71	150.83	176.03
Income Tax Expense	30.49	-9.2	-4.34	4	17.97	25.88
Earnings From Continuing Operations	216.33	-19.77	16.78	52.71	132.87	150.16
Minority Interest in Earnings	-0.92	-0.38	-	-	-	-
Net Income	215.41	-20.16	16.78	52.71	132.87	150.16
Net Income to Common	215.41	-20.16	16.78	52.71	132.87	150.16
Net Income Growth	-	-	-68.16%	-60.33%	-11.52%	118.36%
Shares Outstanding (Basic)	181	166	166	165	166	147
Shares Outstanding (Diluted)	181	166	166	165	166	147
Shares Change (YoY)	8.54%	-0.06%	0.33%	-0.19%	12.59%	18.45%
EPS (Basic)	1.19	-0.12	0.10	0.32	0.80	1.02
EPS (Diluted)	1.19	-0.12	0.10	0.32	0.80	1.02
EPS Growth	-	-	-68.27%	-60.25%	-21.41%	84.35%
Free Cash Flow	121.46	-150.89	-91.39	-332.18	-444.4	-182.49
Free Cash Flow Per Share	0.67	-0.91	-0.55	-2.01	-2.68	-1.24
Dividend Per Share	0.206	0.106	0.270	0.300	0.331	0.273
Dividend Growth	-23.55%	-60.59%	-10.00%	-9.37%	21.11%	-
Gross Margin	26.04%	16.22%	20.66%	21.78%	26.95%	36.77%
Operating Margin	13.95%	1.53%	0.64%	5.96%	13.58%	20.89%
Profit Margin	12.92%	-1.68%	1.65%	5.15%	13.34%	19.31%
Free Cash Flow Margin	7.29%	-12.57%	-8.96%	-32.48%	-44.61%	-23.47%
EBITDA	340.34	131.48	126.96	123.58	163.82	181.52
EBITDA Margin	20.41%	10.95%	12.45%	12.08%	16.44%	23.35%
D&A For EBITDA	107.69	113.13	120.39	62.57	28.54	19.08
EBIT	232.65	18.35	6.57	61.01	135.28	162.43
EBIT Margin	13.95%	1.53%	0.64%	5.96%	13.58%	20.89%
Effective Tax Rate	12.35%	-	-	7.06%	11.91%	14.70%
Revenue as Reported	1,667	1,200	1,020	2,046	996.22	777.46
Advertising Expenses	-	6.83	6.78	3.2	1.71	3.73

Source: S&P Global Market Intelligence. Standard template. Financial Sources.